Related Experiment Video

Updated: Aug 13, 2026

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells
06:33

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells

Published on: February 2, 2024

Targeting insulin-like growth factor pathways

D Yee1

  • 1University of Minnesota Cancer Center, Department of Medicine, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA. yeexx006@umn.edu

British Journal of Cancer
|February 2, 2006
PubMed

Insights

Targeting specific molecules like the type I IGF receptor (IGF-IR) offers a promising cancer therapy strategy. Early clinical trials for IGF-IR targeting agents need to address key issues for successful development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer cell growth, survival, and metastasis are often dependent on specific molecular pathways.
  • Targeted therapies, such as tamoxifen and trastuzumab in breast cancer, have shown significant success.
  • The type I IGF receptor (IGF-IR) pathway is implicated in various cancer types.

Purpose of the Study:

  • To evaluate the type I IGF receptor (IGF-IR) as a potential molecular target for cancer therapy.
  • To review the current landscape of IGF-IR targeting agents and their therapeutic potential.
  • To identify critical issues that need to be addressed in early clinical trials for IGF-IR inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies on IGF-IR in cancer.
  • Analysis of the role of IGF-IR signaling in cancer progression and metastasis.
  • Evaluation of emerging therapeutic strategies targeting the IGF-IR pathway.

Main Results:

  • The IGF-IR pathway plays a crucial role in supporting tumor growth and survival.
  • Targeting IGF-IR has demonstrated preclinical efficacy in various cancer models.
  • Several novel agents targeting the IGF-IR system are advancing towards clinical evaluation.

Conclusions:

  • The IGF-IR represents a viable and important molecular target for developing novel cancer therapies.
  • Successful clinical translation of IGF-IR inhibitors will require careful consideration of patient selection and trial design.
  • Addressing specific challenges in early clinical trials is essential for optimizing the therapeutic benefit of IGF-IR targeting agents.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...